Mitochondrial Toxicity Is Associated with Virological Response in Patients with HIV and Hepatitis C Virus Coinfection Treated with Ribavirin and Highly Active Antiretroviral Therapy

[Guest guest]

http://www.journals.uchicago.edu/doi/abs/10.1086/653214

The Journal of Infectious Diseases 2010;202:156–160

© 2010 by the Infectious Diseases Society of America. All rights reserved.

0022-1899/2010/20201-0019$15.00

DOI: 10.1086/653214

BRIEF REPORT

Mitochondrial Toxicity Is Associated with Virological Response in Patients with

HIV and Hepatitis C Virus Coinfection Treated with Ribavirin and Highly Active

Antiretroviral Therapy

Reiberger,1

Lana Kosi,1

Judith Maresch,2

Florian Breitenecker,3

Berit Payer,1

Fritz Wrba,2

Armin Rieger,3

Alfred Gangl,1 and

Markus Peckâ€Radosavljevic1

Departments of 1Internal Medicine III, Division of Gastroenterology and

Hepatology, 2Pathology, and 3Dermatology, Division of Immunology, Allergy and

Infectious Diseases, Medical University of Vienna, Vienna, Austria

The combination of highly active antiretroviral therapy (HAART) plus ribavirin

(RBV) in patients with human immunodeficiency virus (HIV) and hepatitis C virus

(HCV) coinfection has been reported to cause mitochondrial toxicity (MT).

Sixtyâ€four patients with HIVâ€HCV coinfection who were receiving antiviral

therapy were evaluated for MT. Patients with concomitant HAART showed greater

increases in lactate levels than did patients without HAART, and this difference

was more pronounced in patients who received higher dosages of RBV. The

incidence of pancreatic enzyme elevations and symptomatic pancreatitis was

higher among patients who received HAART and highâ€dose RBV. Hepatic steatosis

increased in patients who received HAART and highâ€dose RBV. Patients who

showed signs of MT achieved higher rates of sustained virologic response than

did patients without MT (73% vs 44%).

Received 27 November 2009; accepted 26 January 2010; electronically published 20

May 2010.

Reprints or correspondence: Prof Dr Markus Peckâ€Radosavljevic, Waehringer

Guertel 18â€20†A1090 Vienna, Austria (markus.peck@...).

Potential conflicts of interest: M.P.â€R. has received research support from

Roche and has received speaker fees from and acted as an advisor to Roche and

Scheringâ€Plough. T.R. has received speaker fees from Roche and

Scheringâ€Plough and travel grants from Roche. L.K. has received travel grants

from Roche. A.R. has received speaker fees and/or travel grants from Gilead,

GlaxoKline, Abbott, BSM, Boehringer, MSD, and Jansenâ€Cilag. All other

authors: no conflicts.

Financial support: Roche.

© 2010. University of Chicago Press. All rights reserved.

_________________________________________________________________

Hotmail is redefining busy with tools for the New Busy. Get more from your

inbox.

http://www.windowslive.com/campaign/thenewbusy?ocid=PID28326::T:WLMTAGL:ON:WL:en\

-US:WM_HMP:042010_2